Companies / Annovis Bio, Inc.

Annovis Bio, Inc.

NYSE: ANVSCIK 1477845MALVERN, PA

Financials · FY2025

Revenue$0
Net income$-28.85M
Total debt—
Cash$14.22M
Diluted EPS$-1.40
Shares outstanding34.6M

Ownership

34.6M shares outstanding · as of May 15, 2026
9.7%Insiders
Ownership
Insiders9.71%3,364,883
Institutions15.62%5,413,277
Public float74.66%25,868,708

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 1

View all →
Insider% of sharesShares
Hoffman Michael BDirector
9.71%3,364,883

Institutional holders 58

View all →
HolderValue% of shares
Vanguard Group Inc$3.19M2.66%
Marshall Wace, LLP$2.65M3.43%
Two Sigma Investments, LP$1.40M1.81%
Susquehanna International Group, LLP$1.05M0.88%
Jane Street Group, LLC$869.0K0.72%
Renaissance Technologies LLC$775.1K1.00%
D.a. Davidson & Co.$556.3K0.46%
Geode Capital Management, LLC$552.2K0.71%
BlackRock, Inc.$464.7K0.72%
Northern Trust Corp$418.2K0.35%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Apr 2, 2026Hoffman Michael B
Director
BuyCommon Stock$1.50M+714K
+27.72%
3,288,539
9.49% of shares
high
May 20, 2026Hoffman Michael B
Director
BuyCommon Stock$104.4K+55K
+1.66%
3,364,883
9.71% of shares
medium
May 20, 2026Hoffman Michael B
Director
BuyCommon Stock$33.9K+19K
+0.57%
3,309,950
9.55% of shares
low

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
ANVSCommon StockEquity03615A108BBG00PN9XD40